表紙
市場調查報告書

遺傳性血管性水腫:流行病學預測(至2030年)

Hereditary Angioedema - Epidemiology Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 948132
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
遺傳性血管性水腫:流行病學預測(至2030年) Hereditary Angioedema - Epidemiology Forecast - 2030
出版日期: 2020年07月01日內容資訊: 英文 100 Pages
簡介

2017年,七個主要國家(美國,德國,法國,意大利,西班牙,英國和日本)的遺傳性血管性水腫(HAE)確診病例總數估計為14,435。美國的患病率最高,為6,566例,其次是法國,在五個歐洲國家中最高,為1,346例,其次是英國。根據美國國家醫學圖書館的資料,遺傳性血管性水腫估計影響50,000人中的1人,患病率佔普通人群的1/10,000至1/150,000。由於缺乏治療,與HAE相關的死亡率約為30%,主要是由於喉頭水腫和窒息。 (美國國立衛生研究院,未註明)

本報告調查了七個主要國家的遺傳性血管性水腫(HAE),並提供了有關疾病,治療,病例和統計信息。

內容

第1章主要見解

第2章流行病學概述

  • 患者總人數:2017年
  • 患者總人數:2030年

第3章執行摘要

第4章組織

第5章流行病學和市場研究方法

第6章疾病概述

  • 簡介
  • 遺傳性血管性水腫的類型
  • 症狀
  • 臨床發現
  • 風險因素
  • HAE的病理生理和免疫學特徵
    • 水腫形成的機制
    • HAE遺傳學
  • 診斷
    • 檢查結果
    • 產前和產後診斷
    • HAE的延遲診斷

第7章流行病學和患者人數

  • 主要發現
  • 7個主要國家:確診率
  • 美國
    • 先決條件和理由
    • 總診斷患病率
    • 特定類型的案例
    • 針對性別的案例
    • 特定年齡段的案例
    • 特定地點的案例
  • 歐洲
  • 德國
  • 法國
  • 意大利
  • 西班牙
  • 英國
  • 日本

第8章治療

  • 按需治療
  • 預防性治療
  • 家庭療法和自我管理
  • WAO管理指南
  • 日本補體學會2010年遺傳性血管性水腫(HAE)指南
  • AAAAI過敏和哮喘治療指南
  • 國際遺傳性血管性水腫指南

第9章潛在需求

第10章案例研究

  • 遺傳性血管性水腫(HAE):復發性腹痛的原因
  • 遺傳性II型血管性水腫:成年後反覆出現嚴重腹痛的最終症狀
  • 一名女性患者的遺傳性I型血管性水腫:病例報告

第11章KOL的觀點

第12章引用

第13章附錄

第14章DelveInsight服務內容

第15章免責聲明

關於Delve Insight的第16章

目錄
Product Code: DIEI0065

DelveInsight's 'Hereditary Angioedema (HAE)- Epidemiology Forecast-2030' report delivers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Hereditary Angioedema (HAE) Disease Understanding

Hereditary Angioedema (HAE) is a rare genetic disorder caused by the deficiency in functional C1 inhibitor (C1INH) that results in recurrent attacks of localized subcutaneous or mucosal edema, most commonly affecting the skin, intestines, upper respiratory tract, and oropharynx. It is classified into three types based on genetic defects such as type I HAE with low levels of C1-INH in the body, type II with poorly functioning C1-INH, or the recently identified types of HAE with normal functioning C1-INH (formerly known as type III HAE). Identification of the novel polymorphisms in several genes leading to modification in the clinical phenotype of HAE is a relatively recent phenomenon.

The clinical features of HAE are recurrent and unpredictable spontaneous edema attacks. Traumas, infections, stress, or medical procedures are potential triggers for HAE attacks, and occasionally, angioedema could be associated with prodromal signs, including erythema marginatum. The severity and timing of HAE attacks are unpredictable, mainly due to the lack of a complete understanding of the underlying mechanisms. Also, swelling without urticaria is the feature of most HAE attacks, regardless of the molecular basis.

HAE is a heterogeneous disease with complex pathophysiology that involves several pathways resulting in the increased production of bradykinin with mutations of multiple molecules in genetic etiology. These could include the Kallikrein gene mutations; Bradykinin gene or its receptor mutations; Kininase 1 gene mutations and loss of function and mutations in gene encoding aminopeptidase and ACE enzymes.

Treatment of HAE has evolved with advancement in understanding the pathogenesis of this disease. It is directed towards either replacing the defective protein or blocking various molecules involved in the production of bradykinin or the bradykinin receptor.

Hereditary Angioedema (HAE) Epidemiology

The Hereditary Angioedema epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Hereditary Angioedema epidemiology segmented as the Total diagnosed Prevalent of Hereditary Angioedema, Gender-specific cases of Hereditary Angioedema, Age-specific cases of Hereditary Angioedema, Type-specific cases of Hereditary Angioedema, Site-specific cases of Hereditary Angioedema, the report includes the Prevalent scenario of Hereditary Angioedema symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Hereditary Angioedema (HAE) Epidemiology

The epidemiology segment also provides the Hereditary Angioedema (HAE) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The total diagnosed prevalent population of Hereditary Angioedema Associated in 7MM countries estimated to be 14,435 cases in 2017.

  • As per the estimates, the United States has the highest prevalent population of Hereditary Angioedema with 6,566 cases in 2017.
  • Among the EU5 countries, France had the highest prevalent population of 1,346 cases, followed by the UK.

Scope of the Report:

  • Hereditary Angioedema (HAE) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • Hereditary Angioedema (HAE) Epidemiology Report and Model provide an overview of the risk factors and global trends of Hereditary Angioedema (HAE) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Hereditary Angioedema (HAE) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Hereditary Angioedema
  • The report provides the segmentation of the Hereditary Angioedema (HAE) epidemiology by Prevalent Cases of Hereditary Angioedema (HAE) in 7MM
  • The report provides the segmentation of the Hereditary Angioedema (HAE) epidemiology by Gender-specific Prevalent Cases of Hereditary Angioedema (HAE) in 7MM
  • The report provides the segmentation of the Hereditary Angioedema (HAE) epidemiology by Age-specific Prevalent Cases of Hereditary Angioedema (HAE) in 7MM
  • The report provides the segmentation of the Hereditary Angioedema (HAE) epidemiology by Type-specific Prevalent Cases of Hereditary Angioedema (HAE) in 7MM
  • The report provides the segmentation of the Hereditary Angioedema (HAE) epidemiology by Site-specific Prevalent Cases of Hereditary Angioedema (HAE) in 7MM

Report Highlights:

  • 11-Year Forecast of Hereditary Angioedema (HAE) epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Hereditary Angioedema (HAE)
  • Prevalent Cases according to segmentation: Gender-specific Prevalence of Hereditary Angioedema (HAE)
  • Prevalent Cases according to segmentation: Age-specific Prevalence of Hereditary Angioedema (HAE)

KOL- Views

We interview KOLs, and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM concerning the patient population about Hereditary Angioedema (HAE)?
  • What are the key findings of the Hereditary Angioedema (HAE) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Hereditary Angioedema (HAE) across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What are the disease risk, burden, and unmet needs of the Hereditary Angioedema?
  • What are the currently available treatments of Hereditary Angioedema?

Reasons to buy:

The Hereditary Angioedema (HAE) Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Hereditary Angioedema (HAE) market
  • Quantify patient populations in the global Hereditary Angioedema (HAE) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Hereditary Angioedema (HAE) therapeutics in each of the markets covered
  • Understand the magnitude of Hereditary Angioedema (HAE) population by its Prevalence cases
  • Understand the magnitude of Hereditary Angioedema (HAE) population by its Gender-specific cases
  • Understand the magnitude of Hereditary Angioedema (HAE) population by its Age-specific cases
  • The Hereditary Angioedema (HAE) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
  • The Hereditary Angioedema (HAE) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

According to the US National Library of Medicine, Hereditary angioedema is estimated to affect 1 in 50,000 people; with the prevalence ranging from 1/10,000 to 1/150,000 of the general population. HAE-associated mortality due to the absence of treatment approaches is about 30% and results from laryngeal edema and asphyxiation predominantly (NIH, n.d.).

Table of Contents

1. Key Insights

2. Hereditary Angioedema (HAE): Epidemiology Overview at a Glance

  • 2.1. Total Patient Share (%) Distribution of HAE in 2017
  • 2.2. Total Patient Share (%) Distribution of HAE in 2030

3. Executive summary

4. Organizations

5. Epidemiology and Market Methodology

6. Hereditary Angioedema (HAE): Disease Overview

  • 6.1. Introduction
  • 6.2. Types of Hereditary Angioedema
  • 6.3. Symptoms
  • 6.4. Clinical Presentation
  • 6.5. Risk Factors
  • 6.6. Pathophysiologic and Immunologic Features of HAE
    • 6.6.1. Mechanisms of Edema Formation
    • 6.6.2. Genetics of HAE
  • 6.7. Diagnosis of Hereditary Angioedema
    • 6.7.1. Laboratory Findings
    • 6.7.2. Prenatal and Postnatal Diagnosis
    • 6.7.3. Delayed Diagnosis of HAE-A Persistent Problem with Serious Consequences

7. Epidemiology and Patient Population

  • 7.1. Key Findings
  • 7.2. Total Diagnosed Prevalent Population of Hereditary Angioedema in 7MM
  • 7.3. United States
    • 7.3.1. Assumptions and Rationale
    • 7.3.2. Total Diagnosed Prevalent Population of Hereditary Angioedema in the United States
    • 7.3.3. Type-Specific cases of Hereditary Angioedema in the US
    • 7.3.4. Gender-Specific cases of Hereditary Angioedema in the US
    • 7.3.5. Age-Specific cases of Hereditary Angioedema in the US
    • 7.3.6. Site-specific cases of Hereditary Angioedema in the US
  • 7.4. Europe
    • 7.4.1. Assumptions and Rationale
  • 7.5. Germany
    • 7.5.1. Total Diagnosed Prevalent Population of Hereditary Angioedema in Germany
    • 7.5.2. Type-Specific cases of Hereditary Angioedema in Germany
    • 7.5.3. Gender-Specific cases of Hereditary Angioedema in Germany
    • 7.5.4. Age-Specific cases of Hereditary Angioedema in Germany
    • 7.5.5. Site-specific cases of Hereditary Angioedema in Germany
  • 7.6. France
    • 7.6.1. Total Diagnosed Prevalent Population of Hereditary Angioedema in France
    • 7.6.2. Type-Specific cases of Hereditary Angioedema in France
    • 7.6.3. Gender-Specific cases of Hereditary Angioedema in France
    • 7.6.4. Age-Specific cases of Hereditary Angioedema in France
    • 7.6.5. Site-specific cases of Hereditary Angioedema in France
  • 7.7. Italy
    • 7.7.1. Total Diagnosed Prevalent Population of Hereditary Angioedema in Italy
    • 7.7.2. Type-Specific cases of Hereditary Angioedema in Italy
    • 7.7.3. Gender-Specific cases of Hereditary Angioedema in Italy
    • 7.7.4. Age-Specific cases of Hereditary Angioedema in Italy
    • 7.7.5. Site-specific cases of Hereditary Angioedema in Italy
  • 7.8. Spain
    • 7.8.1. Total Diagnosed Prevalent Population of Hereditary Angioedema in Spain
    • 7.8.2. Type-Specific cases of Hereditary Angioedema in Spain
    • 7.8.3. Gender-Specific cases of Hereditary Angioedema in Spain
    • 7.8.4. Age-Specific cases of Hereditary Angioedema in Spain
    • 7.8.5. Site-specific cases of Hereditary Angioedema in Spain
  • 7.9. UK
    • 7.9.1. Total Diagnosed Prevalent Population of Hereditary Angioedema in the UK
    • 7.9.2. Type-Specific cases of Hereditary Angioedema in the UK
    • 7.9.3. Gender-Specific cases of Hereditary Angioedema in the UK
    • 7.9.4. Age-Specific cases of Hereditary Angioedema in the UK
    • 7.9.5. Site-specific cases of Hereditary Angioedema in the UK
  • 7.10. Japan
    • 7.10.1. Assumptions and Rationale
    • 7.10.2. Total Diagnosed Prevalent Population of Hereditary Angioedema in Japan
    • 7.10.3. Type-Specific cases of Hereditary Angioedema in Japan
    • 7.10.4. Gender-specific cases of Hereditary Angioedema in Japan
    • 7.10.5. Age-specific cases of Hereditary Angioedema in Japan
    • 7.10.6. Site-specific cases of Hereditary Angioedema in Japan

8. Treatment of Hereditary Angioedema

  • 8.1. On-demand treatment
  • 8.2. Prophylactic treatment
  • 8.3. Home therapy and self-administration
  • 8.4. WAO Guideline for the Management of Hereditary Angioedema
  • 8.5. Guideline for Hereditary Angioedema (HAE) 2010 by the Japanese Association for Complement Research
  • 8.6. AAAAI Allergy and Asthma Medication Guide
  • 8.7. The International Hereditary Angioedema Guideline

9. Unmet Needs

10. Case studies

  • 10.1. Hereditary angioedema (HAE): a cause for recurrent abdominal pain
  • 10.2. Hereditary Angioedema Type II: First Presentation in Adulthood with Recurrent Severe Abdominal Pain
  • 10.3. Hereditary angioedema type I in a female patient: a case report

11. KOL Views

12. Bibliography

13. Appendix

  • 13.1. Report Methodology

14. DelveInsight Capabilities

15. Disclaimer

16. About DelveInsight

List of Tables

  • Table 1: A Comprehensive Table of Hereditary Angioedema Types
  • Table 2: A Comprehensive Table of Hereditary Angioedema Types
  • Table 3: Summary of the mutations described in F12, plasminogen (PLG), and angiopoietin (ANGPT1) genes resulting in HAE.
  • Table 4: Total diagnosed Prevalent Population of Hereditary Angioedema in 7MM (2017-2030)
  • Table 5: Total Diagnosed Prevalent Population of Hereditary angioedema in the US (2017-2030)
  • Table 6: Type-Specific cases of Hereditary Angioedema in the US (2017-2030)
  • Table 7: Gender-Specific cases of Hereditary Angioedema in the US (2017-2030)
  • Table 8: Age-Specific cases of Hereditary Angioedema in the US (2017-2030)
  • Table 9: Site-specific cases of Hereditary Angioedema in the US (2017-2030)
  • Table 10: Total Diagnosed Prevalent Population of Hereditary angioedema in Germany (2017-2030)
  • Table 11: Type-Specific cases of Hereditary Angioedema in Germany (2017-2030)
  • Table 12: Gender-Specific cases of Hereditary Angioedema in Germany (2017-2030)
  • Table 13: Age-Specific cases of Hereditary Angioedema in Germany (2017-2030)
  • Table 14: Site-specific cases of Hereditary Angioedema in Germany (2017-2030)
  • Table 15: Total Diagnosed Prevalent Population of Hereditary angioedema in France (2017-2030)
  • Table 16: Type-Specific cases of Hereditary Angioedema in France (2017-2030)
  • Table 17: Gender-Specific cases of Hereditary Angioedema in France (2017-2030)
  • Table 18: Age-Specific cases of Hereditary Angioedema in France (2017-2030)
  • Table 19: Site-specific cases of Hereditary Angioedema in France (2017-2030)
  • Table 20: Total Diagnosed Prevalent Population of Hereditary angioedema in Italy (2017-2030)
  • Table 21: Type-Specific cases of Hereditary Angioedema in Italy (2017-2030)
  • Table 22: Gender-Specific cases of Hereditary Angioedema in Italy (2017-2030)
  • Table 23: Age-Specific cases of Hereditary Angioedema in Italy (2017-2030)
  • Table 24: Site-specific cases of Hereditary Angioedema in Italy (2017-2030)
  • Table 25: Total Diagnosed Prevalent Population of Hereditary angioedema in Spain (2017-2030)
  • Table 26: Type-Specific cases of Hereditary Angioedema in Spain (2017-2030)
  • Table 27: Gender-Specific cases of Hereditary Angioedema in Spain (2017-2030)
  • Table 28: Age-Specific cases of Hereditary Angioedema in Spain (2017-2030)
  • Table 29: Site-specific cases of Hereditary Angioedema in Spain (2017-2030)
  • Table 30: Total Diagnosed Prevalent Population of Hereditary angioedema in the UK (2017-2030)
  • Table 31: Type-Specific cases of Hereditary Angioedema in the UK (2017-2030)
  • Table 32: Gender-Specific cases of Hereditary Angioedema in the UK (2017-2030)
  • Table 33: Age-Specific cases of Hereditary Angioedema in the UK (2017-2030)
  • Table 34: Site-specific cases of Hereditary Angioedema in the UK (2017-2030)
  • Table 35: Total Diagnosed Prevalent Population of Hereditary angioedema in Japan (2017-2030)
  • Table 36: Type-specific cases of Hereditary Angioedema in Japan (2017-2030)
  • Table 37: Gender-specific cases of Hereditary Angioedema in Japan (2017-2030)
  • Table 38: Age-specific cases of Hereditary Angioedema in Japan (2017-2030)

List of Figures

  • Figure 1: Epidemiology and Market Methodology
  • Figure 2: Risk Factors of Hereditary Angioedema
  • Figure 3: C1 esterase inhibitor prevents the autoactivation of complement C1
  • Figure 4: C1 esterase inhibitor inactivates factors XIIa and XIIf, plasmin, and kallikrein
  • Figure 5: C1 esterase inhibitor modulates complement and contact system activation
  • Figure 6: Mechanism of activation of the contact system
  • Figure 7: Dysregulation of Coagulation, Complement, and Contact Cascades in Hereditary Angioedema
  • Figure 8: Kinin metabolism and the mutual interactions between the kinin, complement, hemostatic and fibrinolytic pathways
  • Figure 9: Summary of the genetic defects leading to the phenotype of hereditary angioedema
  • Figure 10: Various mutations reported in the SERPING1 gene
  • Figure 11: Counteracting influences of angiopoietin 1 and bradykinin on vascular endothelial cells
  • Figure 12: Diagnostic Algorithm for Hereditary Angioedema
  • Figure 13: A proposed diagnostic algorithm for evaluation of a suspected case of hereditary angioedema (HAE with normal C1 inhibitor function requires genetic analysis for diagnosis)
  • Figure 14: Total Diagnosed Prevalent Population of Hereditary Angioedema in 7MM (2017-2030)
  • Figure 15: Total Diagnosed Prevalence of Hereditary angioedema in the US (2017-2030)
  • Figure 16: Type-Specific cases of Hereditary Angioedema in the US (2017-2030)
  • Figure 17: Gender-Specific cases of Hereditary angioedema in the US (2017-2030)
  • Figure 18: Age-Specific cases of Hereditary Angioedema in the US (2017-2030)
  • Figure 19: Site-specific cases of Hereditary Angioedema in the US (2017-2030)
  • Figure 20: Total Diagnosed Prevalence of Hereditary angioedema in Germany (2017-2030)
  • Figure 21: Type-Specific cases of Hereditary Angioedema in Germany (2017-2030)
  • Figure 22: Gender-Specific cases of Hereditary angioedema in Germany (2017-2030)
  • Figure 23: Age-Specific cases of Hereditary Angioedema in Germany (2017-2030)
  • Figure 24: Site-specific cases of Hereditary Angioedema in Germany (2017-2030)
  • Figure 25: Total Diagnosed Prevalence of Hereditary angioedema in France (2017-2030)
  • Figure 26: Type-Specific cases of Hereditary Angioedema in France (2017-2030)
  • Figure 27: Gender-Specific cases of Hereditary angioedema in France (2017-2030)
  • Figure 28: Age-Specific cases of Hereditary Angioedema in France (2017-2030)
  • Figure 29: Site-specific cases of Hereditary Angioedema in France (2017-2030)
  • Figure 30: Total Diagnosed Prevalence of Hereditary angioedema in Italy (2017-2030)
  • Figure 31: Type-Specific cases of Hereditary Angioedema in Italy (2017-2030)
  • Figure 32: Gender-Specific cases of Hereditary angioedema in Italy (2017-2030)
  • Figure 33: Age-Specific cases of Hereditary Angioedema in Italy (2017-2030)
  • Figure 34: Site-specific cases of Hereditary Angioedema in Italy (2017-2030)
  • Figure 35: Total Diagnosed Prevalence of Hereditary angioedema in Spain (2017-2030)
  • Figure 36: Type-Specific cases of Hereditary Angioedema in Spain (2017-2030)
  • Figure 37: Gender-Specific cases of Hereditary angioedema in Spain (2017-2030)
  • Figure 38: Age-Specific cases of Hereditary Angioedema in Spain (2017-2030)
  • Figure 39: Site-specific cases of Hereditary Angioedema in Spain (2017-2030)
  • Figure 40: Total Diagnosed Prevalence of Hereditary angioedema in the UK (2017-2030)
  • Figure 41: Type-Specific cases of Hereditary Angioedema in the UK (2017-2030)
  • Figure 42: Gender-Specific cases of Hereditary angioedema in the UK (2017-2030)
  • Figure 43: Age-Specific cases of Hereditary Angioedema in the UK (2017-2030)
  • Figure 44: Site-specific cases of Hereditary Angioedema in the UK (2017-2030)
  • Figure 45: Total Diagnosed Prevalence of Hereditary angioedema in Japan (2017-2030)
  • Figure 46: Type-specific cases of Hereditary Angioedema in Japan (2017-2030)
  • Figure 47: Gender-specific cases of Hereditary angioedema in Japan (2017-2030)
  • Figure 48: Age-specific cases of Hereditary Angioedema in Japan (2017-2030)
  • Figure 49: Site-specific cases of Hereditary Angioedema in Japan (2017-2030)
  • Figure 50: Unmet Needs